Prosseda et al. achieved IOP reduction in a glaucoma mouse model by enhancing aqueous humor outflow via optogenetic activation of CRY2-OCRL, a CIBN/CRY2-based optogenetic construct.66,67 Additionally, Geeraerts et al. demonstrated reduced RGC degeneration through optogenetic modulation of neuronal activity in the superior colliculus (SC) of mice.68 However, these approaches face significant barriers for clinical translation owing to their invasiveness, requiring open-skull surgery, and reliance on high-intensity light stimulation. Here, CRY2 is linked to glaucoma.